Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 345

1.

1962: 'What manner of men?': Meeting scientists through television.

Boon T.

Public Underst Sci. 2019 Apr;28(3):372-378. doi: 10.1177/0963662518805314. Epub 2018 Nov 4. No abstract available.

PMID:
30392445
2.

Mapping of language brain areas in patients with brain tumors.

Hyder R, Kamel N, Boon TT, Reza F.

Conf Proc IEEE Eng Med Biol Soc. 2015 Aug;2015:626-9. doi: 10.1109/EMBC.2015.7318440.

PMID:
26736340
3.

Sounding the field: recent works in sound studies.

Boon T.

Br J Hist Sci. 2015 Sep;48(3):493-502. doi: 10.1017/S0007087415000291.

PMID:
26256314
4.

'The televising of science is a process of television': establishing Horizon, 1962-1967.

Boon T.

Br J Hist Sci. 2015 Mar;48(1):87-121. doi: 10.1017/S0007087414000405.

PMID:
25833799
5.

Ultrasound of the thigh: focal, compartmental, or comprehensive examination?

Lutterbach-Penna RA, Kalume-Brigido M, Morag Y, Boon T, Jacobson JA, Fessell DP.

AJR Am J Roentgenol. 2014 Nov;203(5):1085-92. doi: 10.2214/AJR.13.12286. Review.

PMID:
25341149
6.

Local immunostimulation leading to rejection of accepted male skin grafts by female mice as a model for cancer immunotherapy.

Bourdeaux C, Lurquin C, Jacquemart I, Lethé B, Brasseur F, van Baren N, Baurain JF, Dyson J, Van Snick J, Uyttenhove C, Boon T.

Proc Natl Acad Sci U S A. 2014 Mar 4;111(9):3502-7. doi: 10.1073/pnas.1401115111. Epub 2014 Feb 18.

7.

Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.

Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T.

Nat Rev Cancer. 2014 Feb;14(2):135-46. doi: 10.1038/nrc3670. Review.

PMID:
24457417
8.

[Developing FGFR inhibitors as potential anti-cancer agents].

Zsákai L, Németh G, Szántai-Kis C, Greff Z, Horváth Z, Szokol B, Baska F, Boon TC, Orfi L, Kéri G.

Acta Pharm Hung. 2013;83(2):47-56. Hungarian.

PMID:
23926649
9.

Management of severe sepsis and septic shock in the Emergency Department: a follow-up survey.

Boon T, Coyle C, Sivayoham N.

Emerg Med J. 2013 Jul;30(7):602. doi: 10.1136/emermed-2012-201982. Epub 2013 Feb 1. No abstract available.

PMID:
23376879
10.

Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases.

Cipponi A, Mercier M, Seremet T, Baurain JF, Théate I, van den Oord J, Stas M, Boon T, Coulie PG, van Baren N.

Cancer Res. 2012 Aug 15;72(16):3997-4007. Epub 2012 Jul 31.

11.

Ultrasound of the rotator cable: prevalence and morphology in asymptomatic shoulders.

Morag Y, Jamadar DA, Boon TA, Bedi A, Caoili EM, Jacobson JA.

AJR Am J Roentgenol. 2012 Jan;198(1):W27-30. doi: 10.2214/AJR.10.5796.

PMID:
22194511
12.

Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases.

Corbière V, Chapiro J, Stroobant V, Ma W, Lurquin C, Lethé B, van Baren N, Van den Eynde BJ, Boon T, Coulie PG.

Cancer Res. 2011 Feb 15;71(4):1253-62. doi: 10.1158/0008-5472.CAN-10-2693. Epub 2011 Jan 7.

13.

A MAGE-C2 antigenic peptide processed by the immunoproteasome is recognized by cytolytic T cells isolated from a melanoma patient after successful immunotherapy.

Ma W, Vigneron N, Chapiro J, Stroobant V, Germeau C, Boon T, Coulie PG, Van den Eynde BJ.

Int J Cancer. 2011 Nov 15;129(10):2427-34. doi: 10.1002/ijc.25911. Epub 2011 Apr 20.

14.

Should ultrasound-guided needle fenestration be considered as a treatment option for recalcitrant patellar tendinopathy? A retrospective study of 47 cases.

Housner JA, Jacobson JA, Morag Y, Pujalte GG, Northway RM, Boon TA.

Clin J Sport Med. 2010 Nov;20(6):488-90. doi: 10.1097/JSM.0b013e3181f3617f.

PMID:
21079447
15.

The changing pattern of primary glomerulonephritis in Singapore and other countries over the past 3 decades.

Woo KT, Chan CM, Mooi CY, -L-Choong H, Tan HK, Foo M, Lee GS, Anantharaman V, Lim CH, Tan CC, Lee EJ, Chiang GS, Tan PH, Boon TH, Fook-Chong S, Wong KS.

Clin Nephrol. 2010 Nov;74(5):372-83.

PMID:
20979946
16.

The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells.

François V, Ottaviani S, Renkvist N, Stockis J, Schuler G, Thielemans K, Colau D, Marchand M, Boon T, Lucas S, van der Bruggen P.

Cancer Res. 2009 May 15;69(10):4335-45. doi: 10.1158/0008-5472.CAN-08-3726. Epub 2009 May 12.

17.

Comparison of stable human Treg and Th clones by transcriptional profiling.

Stockis J, Fink W, François V, Connerotte T, de Smet C, Knoops L, van der Bruggen P, Boon T, Coulie PG, Lucas S.

Eur J Immunol. 2009 Mar;39(3):869-82. doi: 10.1002/eji.200838807.

18.
19.

Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes.

Demotte N, Stroobant V, Courtoy PJ, Van Der Smissen P, Colau D, Luescher IF, Hivroz C, Nicaise J, Squifflet JL, Mourad M, Godelaine D, Boon T, van der Bruggen P.

Immunity. 2008 Mar;28(3):414-24. doi: 10.1016/j.immuni.2008.01.011.

20.

Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells.

Carrasco J, Van Pel A, Neyns B, Lethé B, Brasseur F, Renkvist N, van der Bruggen P, van Baren N, Paulus R, Thielemans K, Boon T, Godelaine D.

J Immunol. 2008 Mar 1;180(5):3585-93.

21.

Musculoskeletal sonography technique: focused versus comprehensive evaluation.

Jamadar DA, Jacobson JA, Caoili EM, Boon TA, Dong Q, Morag Y, Girish G.

AJR Am J Roentgenol. 2008 Jan;190(1):5-9.

PMID:
18094286
22.

Making the modern world.

Boon T.

Hist Today. 2001;51(8):38-44. No abstract available.

PMID:
17542094
23.

Long-term follow-up after laser therapy for penile carcinoma.

Meijer RP, Boon TA, van Venrooij GE, Wijburg CJ.

Urology. 2007 Apr;69(4):759-62.

PMID:
17445665
25.

A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde BJ, Knuth A, Boon T.

J Immunol. 2007 Mar 1;178(5):2617-21. No abstract available.

26.

A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44.

Godelaine D, Carrasco J, Brasseur F, Neyns B, Thielemans K, Boon T, Van Pel A.

Cancer Immunol Immunother. 2007 Jun;56(6):753-9. Epub 2006 Nov 10.

PMID:
17096150
27.

Noxp20 and Noxp70, two new markers of early neuronal differentiation, detected in teratocarcinoma-derived neuroectodermic precursor cells.

Boucquey M, De Plaen E, Locker M, Poliard A, Mouillet-Richard S, Boon T, Kellermann O.

J Neurochem. 2006 Oct;99(2):657-69.

28.

CD45RA on human CD8 T cells is sensitive to the time elapsed since the last antigenic stimulation.

Carrasco J, Godelaine D, Van Pel A, Boon T, van der Bruggen P.

Blood. 2006 Nov 1;108(9):2897-905. Epub 2006 Jul 20.

PMID:
16857986
29.

Lack of tumor recognition by cytolytic T lymphocyte clones recognizing peptide 195-203 encoded by gene MAGE-A3 and presented by HLA-A24 molecules.

So T, Hanagiri T, Chapiro J, Colau D, Brasseur F, Yasumoto K, Boon T, Coulie PG.

Cancer Immunol Immunother. 2007 Feb;56(2):259-69. Epub 2006 Jun 7.

PMID:
16758204
30.

Human T cell responses against melanoma.

Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P.

Annu Rev Immunol. 2006;24:175-208. Review.

PMID:
16551247
31.

Transient down-regulation of DNMT1 methyltransferase leads to activation and stable hypomethylation of MAGE-A1 in melanoma cells.

Loriot A, De Plaen E, Boon T, De Smet C.

J Biol Chem. 2006 Apr 14;281(15):10118-26. Epub 2006 Feb 22.

32.

Destructive cleavage of antigenic peptides either by the immunoproteasome or by the standard proteasome results in differential antigen presentation.

Chapiro J, Claverol S, Piette F, Ma W, Stroobant V, Guillaume B, Gairin JE, Morel S, Burlet-Schiltz O, Monsarrat B, Boon T, Van den Eynde BJ.

J Immunol. 2006 Jan 15;176(2):1053-61.

33.

Unambiguous identification of the expressed MAGE-A genes on a DNA microarray.

Zammatteo N, Davril C, Brasseur F, Hamels S, De Plaen E, Boon T, Remacle J.

Clin Chem. 2005 Dec;51(12):2420-1. No abstract available.

34.

A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinoma.

Takenoyama M, Baurain JF, Yasuda M, So T, Sugaya M, Hanagiri T, Sugio K, Yasumoto K, Boon T, Coulie PG.

Int J Cancer. 2006 Apr 15;118(8):1992-7.

35.

Analysis of a rare melanoma patient with a spontaneous CTL response to a MAGE-A3 peptide presented by HLA-A1.

Hanagiri T, van Baren N, Neyns B, Boon T, Coulie PG.

Cancer Immunol Immunother. 2006 Feb;55(2):178-84. Epub 2005 Sep 27.

PMID:
16187089
36.

A new LAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-A68 tumors.

Sun Z, Lethé B, Zhang Y, Russo V, Colau D, Stroobant V, Boon T, van der Bruggen P.

Cancer Immunol Immunother. 2006 Jun;55(6):644-52. Epub 2005 Sep 27.

PMID:
16187088
37.

Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.

van Baren N, Bonnet MC, Dréno B, Khammari A, Dorval T, Piperno-Neumann S, Liénard D, Speiser D, Marchand M, Brichard VG, Escudier B, Négrier S, Dietrich PY, Maraninchi D, Osanto S, Meyer RG, Ritter G, Moingeon P, Tartaglia J, van der Bruggen P, Coulie PG, Boon T.

J Clin Oncol. 2005 Dec 10;23(35):9008-21. Epub 2005 Aug 1.

PMID:
16061912
38.

Determination of cellularly processed HLA-A2402-restricted novel CTL epitopes derived from two cancer germ line genes, MAGE-A4 and SAGE.

Miyahara Y, Naota H, Wang L, Hiasa A, Goto M, Watanabe M, Kitano S, Okumura S, Takemitsu T, Yuta A, Majima Y, Lemonnier FA, Boon T, Shiku H.

Clin Cancer Res. 2005 Aug 1;11(15):5581-9.

39.

Chasing the tumor thrombus.

de Waal EE, Bruins P, Lahpor JR, Steijling JJ, de Kort LM, Boon TA.

Anesth Analg. 2005 Aug;101(2):332. No abstract available.

PMID:
16037139
40.

A MAGE-1 antigenic peptide recognized by human cytolytic T lymphocytes on HLA-A2 tumor cells.

Ottaviani S, Zhang Y, Boon T, van der Bruggen P.

Cancer Immunol Immunother. 2005 Dec;54(12):1214-20. Epub 2005 Jul 16.

PMID:
16025263
41.

Pelvic exenteration as treatment of recurrent or advanced gynecologic and urologic cancer.

Roos EJ, Van Eijkeren MA, Boon TA, Heintz AP.

Int J Gynecol Cancer. 2005 Jul-Aug;15(4):624-9.

42.

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma.

Kruit WH, van Ojik HH, Brichard VG, Escudier B, Dorval T, Dréno B, Patel P, van Baren N, Avril MF, Piperno S, Khammari A, Stas M, Ritter G, Lethé B, Godelaine D, Brasseur F, Zhang Y, van der Bruggen P, Boon T, Eggermont AM, Marchand M.

Int J Cancer. 2005 Nov 20;117(4):596-604.

43.

A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells.

Zhang Y, Renkvist N, Sun Z, Schuler-Thurner B, Glaichenhaus N, Schuler G, Boon T, van der Bruggen P, Colau D.

Eur J Immunol. 2005 Apr;35(4):1066-75.

44.

Monitoring of anti-vaccine CD4 T cell frequencies in melanoma patients vaccinated with a MAGE-3 protein.

Zhang Y, Sun Z, Nicolay H, Meyer RG, Renkvist N, Stroobant V, Corthals J, Carrasco J, Eggermont AM, Marchand M, Thielemans K, Wölfel T, Boon T, van der Bruggen P.

J Immunol. 2005 Feb 15;174(4):2404-11.

45.

Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen.

Lurquin C, Lethé B, De Plaen E, Corbière V, Théate I, van Baren N, Coulie PG, Boon T.

J Exp Med. 2005 Jan 17;201(2):249-57.

46.

High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens.

Germeau C, Ma W, Schiavetti F, Lurquin C, Henry E, Vigneron N, Brasseur F, Lethé B, De Plaen E, Velu T, Boon T, Coulie PG.

J Exp Med. 2005 Jan 17;201(2):241-8.

47.

Myc represses transcription through recruitment of DNA methyltransferase corepressor.

Brenner C, Deplus R, Didelot C, Loriot A, Viré E, De Smet C, Gutierrez A, Danovi D, Bernard D, Boon T, Pelicci PG, Amati B, Kouzarides T, de Launoit Y, Di Croce L, Fuks F.

EMBO J. 2005 Jan 26;24(2):336-46. Epub 2004 Dec 16.

48.

Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen.

Lonchay C, van der Bruggen P, Connerotte T, Hanagiri T, Coulie P, Colau D, Lucas S, Van Pel A, Thielemans K, van Baren N, Boon T.

Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14631-8. Epub 2004 Sep 27.

49.

Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia.

Tyrrell CJ, Payne H, Tammela TL, Bakke A, Lodding P, Goedhals L, Van Erps P, Boon T, Van De Beek C, Andersson SO, Morris T, Carroll K.

Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):476-83.

PMID:
15380582
50.

MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription.

Laduron S, Deplus R, Zhou S, Kholmanskikh O, Godelaine D, De Smet C, Hayward SD, Fuks F, Boon T, De Plaen E.

Nucleic Acids Res. 2004 Aug 17;32(14):4340-50. Print 2004.

Supplemental Content

Support Center